Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
INZY

INZY - Inozyme Pharma, Inc. Stock Price, Fair Value and News

4.45USD+0.05 (+1.14%)Market Closed

Market Summary

INZY
USD4.45+0.05
Market Closed
1.14%

INZY Stock Price

View Fullscreen

INZY RSI Chart

INZY Valuation

Market Cap

275.3M

Price/Earnings (Trailing)

-3.57

Price/Free Cashflow

-3.55

INZY Price/Sales (Trailing)

INZY Profitability

Return on Equity

-64.89%

Return on Assets

-43.58%

Free Cashflow Yield

-28.19%

INZY Fundamentals

INZY Earnings

Earnings (TTM)

-77.1M

Earnings Growth (Yr)

-34.15%

Earnings Growth (Qtr)

-8.37%

Breaking Down INZY Revenue

Last 7 days

-6.1%

Last 30 days

-4.9%

Last 90 days

-23.3%

Trailing 12 Months

-24.3%

How does INZY drawdown profile look like?

INZY Financial Health

Current Ratio

14.05

Debt/Equity

0.38

Debt/Cashflow

-1.72

INZY Investor Care

Shares Dilution (1Y)

40.47%

Diluted EPS (TTM)

-1.36

Tracking the Latest Insider Buys and Sells of Inozyme Pharma, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 02, 2024
treco douglas a
sold
-52,209
6.94
-7,523
ceo
Apr 01, 2024
treco douglas a
acquired
-
-
25,000
ceo
Mar 28, 2024
winton matthew
acquired
10,616
3.33
3,188
coo
Sep 29, 2023
subramanian sanjay
acquired
8,278
3.57
2,319
svp, cfo
Aug 01, 2023
pivotal bioventure partners fund i, l.p.
bought
4,000,000
4.8
833,333
-
Aug 01, 2023
hopfner robert lorne
bought
4,000,000
4.8
833,333
-
May 12, 2023
hopfner robert lorne
bought
1,429,390
6.25
228,702
-
May 11, 2023
hopfner robert lorne
bought
1,420,610
6.48
219,230
-
Mar 31, 2023
subramanian sanjay
acquired
2,163
2.21
979
svp, cfo
Mar 31, 2023
bolte axel
acquired
10,621
2.21
4,806
-

1–10 of 50

Which funds bought or sold INZY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
sold off
-100
-114,000
-
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-43.42
3,810
222,791
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.93
3,285
36,760
-%
May 15, 2024
Samsara BioCapital, LLC
unchanged
-
5,312,500
11,968,800
1.85%
May 15, 2024
MPM BIOIMPACT LLC
sold off
-100
-1,379,440
-
-%
May 15, 2024
Schonfeld Strategic Advisors LLC
reduced
-31.19
109,906
572,968
-%
May 15, 2024
Lido Advisors, LLC
new
-
131,047
131,047
-%
May 15, 2024
Sofinnova Investments, Inc.
unchanged
-
14,553,000
32,787,200
1.83%
May 15, 2024
Engineers Gate Manager LP
sold off
-100
-61,851
-
-%
May 15, 2024
Parkman Healthcare Partners LLC
added
4.95
802,783
1,707,740
0.21%

1–10 of 48

Are Funds Buying or Selling INZY?

Are funds buying INZY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own INZY
No. of Funds

Unveiling Inozyme Pharma, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 20, 2024
sofinnova venture partners x, l.p.
6.9%
4,280,308
SC 13D/A
Feb 14, 2024
deep track capital, lp
0%
0
SC 13G/A
Feb 14, 2024
new enterprise associates 15, l.p.
-
0
SC 13G/A
Feb 14, 2024
venrock healthcare capital partners ii, l.p.
0.0%
0
SC 13G/A
Feb 14, 2024
rock springs capital management lp
5.96%
3,681,174
SC 13G/A
Feb 14, 2024
eventide asset management, llc
5.15%
3,179,837
SC 13G
Feb 14, 2024
samlyn capital, llc
5.5%
3,372,558
SC 13G
Feb 14, 2024
baker bros. advisors lp
0.0%
0
SC 13G/A
Feb 12, 2024
pivotal bioventure partners fund i, l.p.
4.7%
2,923,110
SC 13D/A
Feb 07, 2024
adage capital partners gp, l.l.c.
8.97%
5,537,500
SC 13G/A

Recent SEC filings of Inozyme Pharma, Inc.

View All Filings
Date Filed Form Type Document
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
4
Insider Trading
Jun 20, 2024
8-K
Current Report
May 07, 2024
8-K
Current Report
May 07, 2024
10-Q
Quarterly Report

Peers (Alternatives to Inozyme Pharma, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.9B
2.0B
9.73% -16.82%
-63.08
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.45
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.36
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.81
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.26
14.48
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.7
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Inozyme Pharma, Inc. News

Latest updates
Marketscreener.com39 hours ago

Inozyme Pharma, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets-11.9%17720120615114213915416210912413814815916917969.0048.00
  Current Assets-11.2%17419620114413413114615410111513114114815116465.0047.00
    Cash Equivalents-40.4%21.0035.0047.0041.0049.0033.0044.0063.0032.0023.0027.0026.0016.0028.0060.0051.0032.00
  Net PPE-10.2%1.001.002.002.002.002.002.002.002.002.003.003.003.003.002.001.000.00
Liabilities-3.7%58.0060.0045.0045.0038.0021.0019.0013.0015.0014.0012.0010.0010.0011.0011.007.003.00
  Current Liabilities-15.5%12.0015.0012.0012.0013.0015.0013.0011.0012.0012.009.007.007.0010.0010.007.003.00
  Long Term Debt0.6%45.0045.0032.0013.0024.004.004.00----------
Shareholder's Equity-15.4%11914016010610311813514994.00109126138149158168--
  Retained Earnings-8.2%-309-285-264-247-232-214-196-179-164-147-128-114-102-91.08-79.96-51.86-34.65
  Additional Paid-In Capital0.4%4284264253533363333313292592572552532512492482.001.00
Shares Outstanding0.1%62.0062.0062.0046.0044.0040.0036.0040.0024.0024.0024.0023.0023.00----
Float----199,466---128---245-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations-32.7%-24,533-18,487-18,868-15,548-17,772-14,400-14,514-14,687-14,160-13,444-12,300-10,033-12,376-10,875-10,201-8,633-6,265---
  Share Based Compensation1.1%1,6911,6731,6721,6002,0921,8861,8492,1851,7522,0221,7521,8131,5771,273786120129-10740.00
Cashflow From Investing260.6%10,394-6,470-44,615-16,32713,7663,218-8,257-22,92622,5629,48713,06219,674573-19,957-99,6665,852-3,408---
Cashflow From Financing-98.7%15912,51669,71523,64220,096-4,21568,33324011.00237112249-986118,86131,9325.00---
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

INZY Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 19,111$ 11,857
General and administrative5,2346,512
Total operating expenses24,34518,369
Loss from operations(24,345)(18,369)
Other income (expense):  
Interest income2,3741,327
Interest expense(1,325)(328)
Other income (expense), net(51)(34)
Other income, net998965
Net loss(23,347)(17,404)
Other comprehensive income (loss):  
Unrealized (losses) gains on available-for-sale securities(156)150
Foreign currency translation adjustment1019
Total other comprehensive income (loss)(146)169
Comprehensive loss(23,493)(17,235)
Net Income (Loss)$ (23,347)$ (17,404)
Net loss per share attributable to common stockholders- basic$ (0.38)$ (0.4)
Net loss per share attributable to common stockholders- diluted$ (0.38)$ (0.4)
Weighted-average common shares and pre-funded warrants outstanding - basic61,772,27943,720,578
Weighted-average common shares and pre-funded warrants outstanding - diluted61,772,27943,720,578

INZY Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 20,618$ 34,588
Short-term investments145,535154,001
Prepaid expenses and other current assets8,1717,661
Total current assets174,324196,250
Property and equipment, net1,3161,466
Restricted cash311311
Right-of-use assets9921,126
Prepaid expenses, net of current portion01,694
Total assets176,943200,847
Current liabilities:  
Accounts payable2,1661,166
Accrued expenses9,30612,610
Operating lease liabilities934910
Total current liabilities12,40614,686
Operating lease liabilities, net of current portion669913
Long term debt, net45,03244,769
Total liabilities58,10760,368
Commitments and contingencies (Note 7)
Stockholders’ equity:  
Preferred stock, $0.0001 par value - 5,000,000 shares authorized at March 31, 2023 and December 31, 2023; no shares issued and outstanding at March 31, 2023 or December 31, 202300
Common Stock, $0.0001 par value - 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 61,816,509 shares issued and outstanding at March 31, 2024 and 61,768,771 shares issued and outstanding at December 31, 202366
Additional paid in-capital428,212426,362
Accumulated other comprehensive income (loss)(105)41
Accumulated deficit(309,277)(285,930)
Total stockholders’ equity118,836140,479
Total liabilities and stockholders’ equity$ 176,943$ 200,847
INZY
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEinozyme.com
 INDUSTRYBiotechnology
 EMPLOYEES56

Inozyme Pharma, Inc. Frequently Asked Questions


What is the ticker symbol for Inozyme Pharma, Inc.? What does INZY stand for in stocks?

INZY is the stock ticker symbol of Inozyme Pharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inozyme Pharma, Inc. (INZY)?

As of Fri Jun 21 2024, market cap of Inozyme Pharma, Inc. is 275.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INZY stock?

You can check INZY's fair value in chart for subscribers.

What is the fair value of INZY stock?

You can check INZY's fair value in chart for subscribers. The fair value of Inozyme Pharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inozyme Pharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for INZY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inozyme Pharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether INZY is over valued or under valued. Whether Inozyme Pharma, Inc. is cheap or expensive depends on the assumptions which impact Inozyme Pharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INZY.